STR

Promega Kit Enables European Forensic Labs to Solve Challenging Cold Cases

Retrieved on: 
Martedì, Maggio 7, 2024
Health, Biometrics, Health Technology, Genetics, Other Science, Science, Biotechnology, Multimedia, Spectrum, STR, DNA, Promega

Forensic laboratories in Europe now have a new DNA analysis kit to efficiently process challenging casework samples.

Key Points: 
  • Forensic laboratories in Europe now have a new DNA analysis kit to efficiently process challenging casework samples.
  • The PowerPlex® 18E System, launched by Promega Corporation, uses eight-color short tandem repeat (STR) analysis chemistry to extract more usable information from challenging samples.
  • The kit includes all DNA markers recommended by the European Network of Forensic Science Institutes (ENFSI).
  • “This kit meets European forensic laboratories’ unique needs while also giving them more information from challenging DNA samples compared to earlier chemistries.”
    STR analysis is the most widely used tool in human identification efforts.

Jeffrey Earnhardt and the No. 26 ForeverLawn Toyota GR Supra Return at Talladega

Retrieved on: 
Martedì, Aprile 16, 2024
Earnhardt, FOX, SHR, Toyota Supra (J29/DB), Social media, Toyota, Creation, Talladega Superspeedway, Critical path, Sam Hunt, Black, Athlete, Ark Encounter, STR, Creation Museum, Organization

LOUISVILLE, OH, April 16, 2024 (GLOBE NEWSWIRE) -- ForeverLawn, Inc.® is excited to return to the track for the Ag-Pro 300 at the Talladega Superspeedway.

Key Points: 
  • LOUISVILLE, OH, April 16, 2024 (GLOBE NEWSWIRE) -- ForeverLawn, Inc.® is excited to return to the track for the Ag-Pro 300 at the Talladega Superspeedway.
  • “I’m amped to be headed back to ‘Dega in the Black and Green Grass Machine,” says Earnhardt.
  • 26 Toyota GR Supra for Sam Hunt Racing, which will feature the familiar Black and Green Grass Machine paint scheme.
  • Viewers can follow Jeffrey Earnhardt and the Black and Green Grass Machine on social media and by watching on FOX.

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

Retrieved on: 
Venerdì, Aprile 26, 2024
Research, Pharmaceutical, Consumer, Infectious Diseases, Hospitals, Clinical Trials, Science, Baby, Maternity, Biotechnology, Women, AIDS, FDA, Health, University, Boxed warning, Gilead Sciences, Safety, PWH, Pregnancy, Pharmacokinetics, Woman, Food, CDC, Doctor of Philosophy, PCR, Tablet, Incidence, HIV-1, STR, HIV, DHHS, Associate, Plasma, National Medical Association

This update makes Biktarvy the only second-generation integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) with in-label clinical trial data and FDA approval in virologically suppressed adults who are pregnant.

Key Points: 
  • This update makes Biktarvy the only second-generation integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) with in-label clinical trial data and FDA approval in virologically suppressed adults who are pregnant.
  • Additionally, guidelines recommend continuing Biktarvy for PWH already on treatment who are virologically suppressed and tolerating treatment well who may become pregnant.
  • “This label update marks an important milestone for Biktarvy, reinforcing its efficacy profile for pregnant PWH, an often understudied and most vulnerable community in clinical research,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences.
  • “Not only is Biktarvy an alternative regimen for use in pregnancy, but people of childbearing potential can also remain on Biktarvy if they become pregnant.

Guesty Raises $130M to Accelerate Global Expansion

Retrieved on: 
Mercoledì, Aprile 10, 2024
MSD, Darktrace, BDT, Investment, Capital, SMB, AI, Travel, API, STR analysis, Principal, Work, KKR, STR, OutSystems, Growth, Tourism

NEW YORK, April 10, 2024 /PRNewswire/ -- Guesty, the leading property management software platform for the short-term rental ("STR") and hospitality industry, today announced a $130M Series F funding round led by leading global investment firm KKR. Inovia Capital, together with existing investors Apax, BDT & MSD Partners and Sixth Street, also joined the round, extending their support following Guesty's significant expansion and sustained growth. This new round of funding will support continued development of Guesty's best-in-class enterprise-level platform for property managers and drive market consolidation to grow the company's global footprint. Stephen Shanley, Partner at KKR and Head of Tech Growth in Europe; Lauriane Requena, Principal at KKR Tech Growth, and Dennis Kavelman, Inovia Capital Partner, join Guesty's Board of Directors following this investment.

Key Points: 
  • Inovia Capital, together with existing investors Apax, BDT & MSD Partners and Sixth Street, also joined the round, extending their support following Guesty's significant expansion and sustained growth.
  • This new round of funding will support continued development of Guesty's best-in-class enterprise-level platform for property managers and drive market consolidation to grow the company's global footprint.
  • Operating in over 80 countries, Guesty is the most comprehensive and easy-to-use platform on the market today.
  • Guesty's new funding will be used for expansion across the US, enhancing vacation rental offerings with innovative features.

Savage Tooele Railroad Line in Utah Wins Surface Transportation Board Approval

Retrieved on: 
Mercoledì, Aprile 3, 2024
Longevity, STR, STB, Union Pacific Railroad, Environmental impact assessment, Transport, Savage, Surface Transportation Board, Environmental analysis, Rail transport by country, Line, Rehabilitation

SALT LAKE CITY, April 03, 2024 (GLOBE NEWSWIRE) -- The Surface Transportation Board (STB) has granted Savage Tooele Railroad Company (STR) the authority to build and operate approximately 11 miles of rail line in Tooele County, Utah, including the rehabilitation of existing track.

Key Points: 
  • SALT LAKE CITY, April 03, 2024 (GLOBE NEWSWIRE) -- The Surface Transportation Board (STB) has granted Savage Tooele Railroad Company (STR) the authority to build and operate approximately 11 miles of rail line in Tooele County, Utah, including the rehabilitation of existing track.
  • The STR rail line will connect to Union Pacific Railroad for tenants of the Lakeview Business Park in Grantsville, Utah, linking supply chains and providing an alternative to truck-only transportation with a more environmentally-friendly option.
  • STR is one of the only new railroads approved in the U.S. this year and one of the first railroads owned and operated by a Utah-headquartered company in the state’s history.
  • “I want to congratulate Savage Tooele Railroad on the approval of their Tooele Valley rail project by the Surface Transportation Board,” said Utah Governor Spencer J. Cox.

The Dawn of a New Trading Era STrade Announces the Launch of STR Token

Retrieved on: 
Mercoledì, Aprile 3, 2024
Crypto, Intelligence, Algorithm, Visa, Artificial intelligence, Growth, STR, AI, Cryptocurrency

DILTA technology is the backbone of STrade, utilizing state-of-the-art machine learning algorithms to analyze market trends and optimize trading strategies in real-time.

Key Points: 
  • DILTA technology is the backbone of STrade, utilizing state-of-the-art machine learning algorithms to analyze market trends and optimize trading strategies in real-time.
  • The launch of the STR token is not just a testament to STrade's commitment to innovation but also a gateway for investors to be a part of the future of trading.
  • The launch of STR token is anticipated to herald a new era in trading, where technology and tokenomics come together to empower investors and traders alike.
  • With the STR token, STrade is not just creating a new token; it's crafting the future of trading.

Apple Hospitality REIT Acquires the AC Hotel by Marriott Washington DC Convention Center

Retrieved on: 
Mercoledì, Marzo 27, 2024
Lodging, Commercial Building & Real Estate, Destinations, Construction & Property, Vacation, REIT, Travel, Professional Services, Tourist Attractions, Other Travel, Finance, Washington Convention Center, Real estate, Growth, STR, Embassy Suites by Hilton, Walter, Hospitality, Acquisition, Capital One Arena, Investment, Hotel, Government, Motto, LEED

Apple Hospitality REIT, Inc. (NYSE: APLE) (the “Company” or “Apple Hospitality”) today announced the acquisition of the 234-room AC Hotel by Marriott Washington DC Convention Center (the “Hotel”) for approximately $116.8 million, or $499,000 per key.

Key Points: 
  • Apple Hospitality REIT, Inc. (NYSE: APLE) (the “Company” or “Apple Hospitality”) today announced the acquisition of the 234-room AC Hotel by Marriott Washington DC Convention Center (the “Hotel”) for approximately $116.8 million, or $499,000 per key.
  • “We are pleased to expand our portfolio with the acquisition of the AC Hotel Washington DC Convention Center and are thrilled to establish a presence in downtown Washington, D.C., a market we have tracked and wanted to have a presence in for some time,” said Nelson Knight, President, Real Estate and Investments of Apple Hospitality.
  • As we look for and continue to underwrite acquisition opportunities, we are dedicated to pursuing transactions that meaningfully enhance our portfolio and maximize long-term value for our shareholders.”
    The AC Hotel Washington DC Convention Center opened in October 2020 and is located at 601 K Street NW, Washington, D.C.
  • Following the acquisition of the AC Hotel Washington DC Convention Center, the Apple Hospitality hotel portfolio includes 224 hotels with 29,886 guest rooms geographically diversified throughout 37 states and the District of Columbia.

Oxford Nanopore Technologies and SeqOne Partner to Support Interpretation of Nanopore Sequencing in Clinical Use

Retrieved on: 
Lunedì, Marzo 11, 2024
Health Technology, Technology, Nanotechnology, Pharmaceutical, Oncology, Professional Services, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, WGS, Nephrology, APHP, STR, Single-nucleotide polymorphism, Partnership, CFH, Patient, Chelsea Handler, RUO, HPO, Oxford Nanopore Technologies, Thrombotic microangiopathy, Developed country, Nanopore sequencing, Thrombosis, CNV, Pharmaceutical industry

Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.

Key Points: 
  • Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.
  • It also enables one-click HPO extraction from clinical notes with the DiagAI Notes2HPO large language model.
  • In the future, the collaboration will deliver other variant interpretation applications addressing the needs of cancer predisposition and somatic analysis.
  • “We are excited to collaborate with SeqOne to provide end-to-end solutions for our customers in rare disease and oncology.

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Retrieved on: 
Mercoledì, Marzo 6, 2024
Biotechnology, AIDS, Hospitals, Health, Pharmaceutical, ARV, Week, Research, Doctor of Philosophy, CROI, Science, CAPRISA, TLD, Fever, Coinfection, TB, STR, Common, Health care, Organization, DTG, Drug resistance, Genotype, HBV, Fungal infection, Principal, Rifampicin, Seroconversion, Tablet, ALT, TDF, Conference, Safety, Biomarker, Pharmacokinetics, Integrase, Metabolism, Emtricitabine, Aes, Gilead Sciences, MD, FDA, Upper respiratory tract infection, Food, Cell, Risk, Prevalence, COVID-19, Death, Patient, HIV/AIDS, Tuberculosis, INSIGHT, HIV, Vaccine

“People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.

Key Points: 
  • “People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.
  • The ALLIANCE trial is the first randomized clinical trial of TAF- vs TDF-based regimens in treatment naïve adults with HIV /HBV coinfection.
  • Additionally, ALLIANCE participants treated with Biktarvy exhibited numerically higher levels of HBV viral suppression and seroconversion.
  • The primary outcome measure is viral suppression rates at Week 24, defined as HIV-1 RNA ˂50 copies/mL.

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on: 
Lunedì, Febbraio 26, 2024
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, Senior, Hepatitis B, CROI, Hook effect, RWE, STR, Viral, Virus, DTG, Mortality, Lenacapavir, Hepatitis, HBV, Vesatolimod, Fungal infection, HIV-1, MDR, PWH, HDV, Boxed warning, European, Islatravir, Tablet, European Commission, Liver disease, Omicron, Conference, Safety, ART, Civil service commission, Abstract, Bictegravir, Natural history, Virology, Emtricitabine, Gilead Sciences, MD, Food, Coinfection, Immunodeficiency, European Economic Area, Risk, Prevalence, Dexamethasone, Patient, Tuberculosis, INSIGHT, HIV, Pharmaceutical industry

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points: 
  • Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
  • Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
  • Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
  • Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.